查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1968532

滤泡刺激素市场－全球产业规模、份额、趋势、机会、预测：按类型、应用、地区和竞争格局划分，2021-2031年

Follicle Stimulating Hormone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application (Infertility Treatment, Assisted Reproductive Application, Others), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球滤泡刺激素市场预计将从 2025 年的 19.1 亿美元成长到 2031 年的 26.9 亿美元，复合年增长率达到 5.87%。

滤泡刺激素由脑下垂体前叶分泌，是一种重要的促性腺激素，它调节女性卵泡发育和男性精子生成。该市场的成长主要受不孕症上升和生育年龄延迟等文化趋势的驱动，这两种趋势都导致人们对辅助生殖技术的依赖性增强。人口结构的变化也支撑了这一需求的激增，这些变化表明全球自然生育率正在下降。例如，美国生殖医学会2025年发布的报告显示，2024年全球平均生育率为每人2.2个婴儿。

市场概览
预测期 2027-2031
市场规模：2025年 19.1亿美元
市场规模：2031年 26.9亿美元
复合年增长率：2026-2031年 5.87%
成长最快的细分市场 不孕症治疗
最大的市场 北美洲

儘管需求成长带来利好，但市场仍面临许多挑战。这些挑战主要源自于不孕症治疗费用极高，以及许多地区缺乏足够的保险保障。这些经济障碍限制了患者获得必要治疗的机会，并造成不同经济区域间治疗机会的显着不平等，阻碍了市场的潜在成长。

市场驱动因素

辅助生殖技术（ART）的日益普及是市场成长的主要驱动力，因为诸如体外受精（IVF）等手术严重依赖外源性促性腺激素来促进控制性卵巢过度刺激。在这些临床情况下，滤泡刺激素对于募集多个卵泡至关重要，从而最大限度地提高卵子回收率，增加怀孕数率。随着全球治疗数量的增加，这种医疗需求也带来了对药物的稳定需求。特别是，根据英国人类受精与胚胎管理局（HFEA）2024年6月发布的数据，2022年英国的IVF週期数约为77,000个，比疫情前增加了11%。

同时，生育年龄延迟的社会趋势进一步加剧了对这类医疗干预的需求，因为母亲年龄的增长与卵巢储备下降和卵子品质恶化密切相关。这种族群结构的变化使得使用高剂量促卵泡激素（FSH）通讯协定对于确保成功怀孕至关重要。东亚地区的数据也印证了这项需求的迫切性。根据韩国统计厅2024年8月发布的报告，2023年韩国的总合生育率骤降至历史新低，仅每位女性0.72个孩子。因此，这项需求催生了强劲的商业环境。欧加农公司2024年的报告显示，其女性健康业务部门第三季的营收成长了5%，这主要得益于生育治疗产品的强劲销售。

市场挑战

高昂的生育治疗费用是全球滤泡刺激素）市场成长的主要障碍。由于滤泡刺激素是辅助生殖技术中的关键药物成分，这些治疗的高昂费用限制了只有经济条件充足的人才能获得治疗机会。这种经济障碍导致全球治疗週期数量下降，直接抑制了对该激素的需求，并限制了整体市场收入。在医疗保健资源匮乏的地区，这种经济负担尤其沉重，迫使患者自费承担费用，并常常导致较高的治疗中断率。

此外，缺乏全面的保险覆盖加剧了这个问题，扩大了临床需求与医疗服务取得之间的差距。如果没有经济支持，多次治疗週期的累积费用对大多数人来说将难以承受，从而有效地限制了市场覆盖范围。根据美国生殖医学会2024年报告，美国一次体外受精（IVF）週期的平均费用在12,000美元至15,000美元之间。如此沉重的经济负担凸显了阻碍IVF普及和市场成长的经济障碍的严重性。

市场趋势

生物相似药FSH疗法的引进和商业化正在从根本上改变竞争格局，为传统的重组产品提供更经济实惠的替代方案。随着关键原厂生物製药专利的到期，生物相似药生产商正积极利用低价策略扩大市场份额，迫使现有公司大幅降价以维持其处方量。价格下降一方面给传统品牌的获利能力带来压力，另一方面透过降低治疗週期成本，提高了生育治疗的可近性。例如，欧加农公司在2025年2月发布的报告中揭露，其旗舰生育产品Follistim AQ在2024年全年的全球销售额下降了10%。这一下降主要归因于竞争对手的降价和日益激烈的全球竞争。

同时，人工智慧（AI）在精准给药策略中的应用，正透过实现高度个人化的治疗通讯协定，彻底改变卵巢刺激疗法。医疗专业人员越来越多地使用基于人工智慧的演算法来评估患者特异性生物标记，例如基准荷尔蒙水平和卵泡计数，并确定每个週期的最佳促卵泡激素（FSH）剂量。这项技术进步透过摒弃统一的标准化给药方法，降低了卵巢过度刺激症候群的风险，并提高了取卵效率。根据《IVF-Worldwide》杂誌2025年5月刊报道，到2025年，生育专家在精准给药和胚胎选择等工作中使用人工智慧工具的比例将增长至约29.2%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球滤泡刺激素市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（重组FSH、尿源性FSH）
    • 依应用领域（不孕症治疗、辅助生殖技术（ART）、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美滤泡刺激素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲滤泡刺激素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区滤泡刺激素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲滤泡刺激素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲滤泡刺激素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球滤泡刺激素市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Merck KgAa
  • Creative BioMart inc.
  • Midas Pharma GmbH
  • Genpharm Services
  • Livzon Pharmaceutical Group Inc
  • Shanghai Techwell Biopharmaceutical Co., Ltd
  • Medix Biochemica USA Inc.
  • Biogenix Inc.Pvt.Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19204

The Global Follicle Stimulating Hormone Market is projected to expand from USD 1.91 Billion in 2025 to USD 2.69 Billion by 2031, achieving a compound annual growth rate of 5.87%. Produced by the anterior pituitary gland, follicle stimulating hormone is a vital gonadotropin that orchestrates the development of ovarian follicles in women and regulates spermatogenesis in men. The market is primarily propelled by rising infertility rates and a cultural trend toward postponing childbirth, both of which increase the reliance on assisted reproductive technologies. This surge in demand is corroborated by demographic shifts showing a global reduction in natural birth rates; for instance, the American Society for Reproductive Medicine noted in 2025 that the average global fertility rate stood at 2.2 births per woman in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.91 Billion
Market Size 2031USD 2.69 Billion
CAGR 2026-20315.87%
Fastest Growing SegmentInfertility Treatment
Largest MarketNorth America

Despite these favorable demand drivers, the market encounters significant obstacles stemming from the exorbitant costs of fertility treatments and the scarcity of adequate insurance coverage in numerous areas. These financial hurdles limit patient access to essential therapies and generate marked inequalities in treatment availability across various economic regions, ultimately retarding the market's potential growth.

Market Driver

The rising adoption of Assisted Reproductive Technologies (ART) acts as a primary engine for market growth, given that procedures like In Vitro Fertilization (IVF) depend heavily on exogenous gonadotropins to stimulate controlled ovarian hyperstimulation. In these clinical scenarios, Follicle Stimulating Hormone is crucial for recruiting multiple ovarian follicles, which maximizes the harvest of viable oocytes and enhances the likelihood of conception. This medical requirement creates a steady demand for pharmaceuticals as treatment volumes increase worldwide; notably, the Human Fertilisation and Embryology Authority reported in June 2024 that IVF cycles in the UK rose to approximately 77,000 in 2022, representing an 11% increase over pre-pandemic figures.

Concurrently, the societal trend toward delayed childbearing intensifies the need for these medical interventions, as increased maternal age is associated with lower ovarian reserves and compromised oocyte quality. This demographic shift necessitates the use of higher-dosage FSH protocols to secure successful pregnancy results. The severity of this need is highlighted by data from East Asia, where Statistics Korea reported in August 2024 that the total fertility rate plummeted to a historic low of 0.72 children per woman in 2023. Consequently, this demand fosters a strong commercial landscape, illustrated by Organon's 2024 report indicating a 5% revenue increase in its Women's Health segment during the third quarter, largely attributed to the robust sales of fertility products.

Market Challenge

The high expenses linked to fertility treatments present a major hurdle that constrains the growth of the Global Follicle Stimulating Hormone Market. As follicle stimulating hormone is a key pharmaceutical ingredient in assisted reproductive technology regimens, the steep price of these procedures restricts the potential patient population to those with substantial financial resources. This economic exclusion results in fewer treatment cycles being initiated worldwide, which directly suppresses demand for the hormone and limits overall market revenue. The financial strain is especially severe in areas without strong public healthcare support, compelling patients to cover costs out-of-pocket and frequently leading to high rates of treatment discontinuation.

Moreover, the absence of comprehensive insurance coverage worsens this issue by expanding the divide between clinical necessity and access to care. Lacking financial aid, the accumulated costs of required multiple cycles become unaffordable for most people, effectively limiting market reach. As reported by the American Society for Reproductive Medicine in 2024, the average cost for a single in vitro fertilization cycle in the United States fell between $12,000 and $15,000. This significant financial demand underscores the gravity of the economic barriers that hinder widespread usage and impede the market's growth trajectory.

Market Trends

The introduction and commercialization of biosimilar FSH therapies are fundamentally transforming the competitive environment by offering more affordable alternatives to traditional recombinant products. As patents on leading originator biologics expire, manufacturers of biosimilars are aggressively gaining market share through lower pricing, forcing established companies to offer steeper discounts to keep their formulary spots. This trend of price erosion is cutting into the revenue of legacy brands while simultaneously making fertility treatments more accessible by reducing cycle costs. For example, Organon revealed in its February 2025 report that global sales of its flagship fertility product, Follistim AQ, fell by 10% throughout 2024, a decline largely blamed on competitive discounting and heightened global rivalry.

At the same time, the incorporation of artificial intelligence into precision dosing strategies is revolutionizing ovarian stimulation by facilitating highly customized treatment protocols. Medical professionals are increasingly utilizing AI-based algorithms to evaluate patient-specific biomarkers, such as baseline hormone levels and follicle counts, to determine the ideal FSH dosage for each cycle. This technological advancement reduces the risk of ovarian hyperstimulation syndrome and enhances oocyte retrieval efficiency by abandoning generic, standardized dosing methods. According to a May 2025 article in the Journal of IVF-Worldwide, the usage of AI tools by fertility specialists for tasks like precision dosing and embryo selection increased to approximately 29.2% in 2025.

Key Market Players

  • Merck KgAa
  • Creative BioMart inc.
  • Midas Pharma GmbH
  • Genpharm Services
  • Livzon Pharmaceutical Group Inc
  • Shanghai Techwell Biopharmaceutical Co., Ltd
  • Medix Biochemica USA Inc.
  • Biogenix Inc.Pvt.Ltd.

Report Scope

In this report, the Global Follicle Stimulating Hormone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Follicle Stimulating Hormone Market, By Type

  • Recombinant FSH
  • Urinary FSH

Follicle Stimulating Hormone Market, By Application

  • Infertility Treatment
  • Assisted Reproductive Application (ART)
  • Others

Follicle Stimulating Hormone Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Follicle Stimulating Hormone Market.

Available Customizations:

Global Follicle Stimulating Hormone Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Follicle Stimulating Hormone Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Recombinant FSH, Urinary FSH)
    • 5.2.2. By Application (Infertility Treatment, Assisted Reproductive Application (ART), Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Follicle Stimulating Hormone Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Follicle Stimulating Hormone Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Follicle Stimulating Hormone Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Follicle Stimulating Hormone Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Follicle Stimulating Hormone Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Follicle Stimulating Hormone Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Follicle Stimulating Hormone Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Follicle Stimulating Hormone Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Follicle Stimulating Hormone Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Follicle Stimulating Hormone Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Follicle Stimulating Hormone Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Follicle Stimulating Hormone Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Follicle Stimulating Hormone Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Follicle Stimulating Hormone Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Follicle Stimulating Hormone Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Follicle Stimulating Hormone Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Follicle Stimulating Hormone Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Follicle Stimulating Hormone Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Follicle Stimulating Hormone Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Follicle Stimulating Hormone Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Follicle Stimulating Hormone Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Follicle Stimulating Hormone Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Follicle Stimulating Hormone Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Follicle Stimulating Hormone Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Follicle Stimulating Hormone Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck KgAa
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Creative BioMart inc.
  • 15.3. Midas Pharma GmbH
  • 15.4. Genpharm Services
  • 15.5. Livzon Pharmaceutical Group Inc
  • 15.6. Shanghai Techwell Biopharmaceutical Co., Ltd
  • 15.7. Medix Biochemica USA Inc.
  • 15.8. Biogenix Inc.Pvt.Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer